Related Article from Simplifying the Energy Balance Message for Breast Cancer Prevention

Related Article from Simplifying the Energy Balance Message for Breast Cancer Preventio

Supplemental Tables 1-5 from Omega-3 and Omega-6 Fatty Acids in Blood and Breast Tissue of High-Risk Women and Association with Atypical Cytomorphology

Supplemental Tables 1-5. Supplemental Table 1: comparison of fatty acid composition by cytologic atypia or not. Supplemental Table 2: Comparison of fatty acid composition of plasma phospholipids (PLs) by evidence of cytology atypia. Supplemental Table 3: Comparison of fatty acid composition of plasma triacylglycerides (TAGs) by evidence of cytology atypia. Supplemental Table 4: Comparison of fatty acid composition of breast phospholipids (PLs) by evidence of cytology atypia. Supplemental Table 5: Comparison of fatty acid composition of breast triacylglycerides (TAGs) by evidence of cytology atypia.</p

Supplemental File 1 from Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer

Summary of Assessment of Ki-67 Staining Problems. Supplementary Table 1: Summary of Values, Changes, and Statistical Results for Ki-67 Assessments. Supplementary Table 2: Summary of Analyses of Different Subsets of Subjects.</p

Supplemental Table 1 from Omega-3-Acid Ethyl Esters Block the Protumorigenic Effects of Obesity in Mouse Models of Postmenopausal Basal-like and Claudin-Low Breast Cancer

Supplemental Table 1. Pilot dosing study - 8 weeks ad libitum consumption. Individual values (n=2) are shown.</p

Supplementary Figure 1 Legend from Omega-3-Acid Ethyl Esters Block the Protumorigenic Effects of Obesity in Mouse Models of Postmenopausal Basal-like and Claudin-Low Breast Cancer

Supplemental Figure 1. EPA+DHA supplementation does not significantly alter serum levels of A.</p

Supplemental Figure 1 from Omega-3-Acid Ethyl Esters Block the Protumorigenic Effects of Obesity in Mouse Models of Postmenopausal Basal-like and Claudin-Low Breast Cancer

Supplemental Figure 1. EPA+DHA supplementation does not significantly alter serum levels of A. TNF-a; B. MCP-1; C. Insulin; D. IGF-1; or E. IGF-BP3 in control or DIO mice (n=10 per group). Data shown are means {plus minus} SEM, statistically significant (P<0.05) differences are indicated by different letters.</p

Supplementary Data from Effect of Bazedoxifene and Conjugated Estrogen (Duavee) on Breast Cancer Risk Biomarkers in High-Risk Women: A Pilot Study

Supplementary Tables 1-3</p

Supplemental Files from Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women

Supplemental Figure 1: CONSORT diagram for flow of potential and actual subjects enrolled on study. Supplementary Table 1. Demographic and risk information at baseline. Supplementary Table 2. Change in anthropomorphic variables. Supplementary Table 3: Changes in levels of cytokines and adipokines in RPFNA specimens, by Luminex. Supplementary Table 4: Changes in levels of mRNA in RPFNA specimens, by RT-qPCR. Supplementary Table 5: Changes in levels of all peptides and specific phosphopeptides in RPFNA specimens, by Reverse Phase Protein Array.</p

Supplemental Files from Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women

Supplemental Figure 1: CONSORT diagram for flow of potential and actual subjects enrolled on study. Supplementary Table 1. Demographic and risk information at baseline. Supplementary Table 2. Change in fatty acid content in all five compartments. Supplementary Table 3. Change in anthropomorphic variables. Supplementary Table 4: Changes in levels of cytokines and adipokines in RPFNA specimens, by Luminex. Supplementary Table 5: Changes in levels of mRNA in RPFNA specimens, by RT-qPCR. Supplementary Table 6: Changes in levels of all peptides and specific phosphopeptides in RPFNA specimens, by Reverse Phase Protein Array.</p

Supplementary Figures and Tables from Randomized Phase IIB Trial of the Lignan Secoisolariciresinol Diglucoside in Premenopausal Women at Increased Risk for Development of Breast Cancer

Supplementary Figures and Tables</p